Side-by-side breakdowns - how two compounds or categories are alike, how they differ, and what the literature usually measures. Mechanisms, not verdicts.
13 articles tagged “Comparisons”
Des(1-3) IGF-1 vs Long R3 IGF-1 compared - structure, IGF-binding-protein affinity, half-life and potency, the recombinant-protein research context, and the WADA/USADA prohibited status with health-risk warnings. Research use only; not for human use.
GMP and pharmacopoeia standards vs research-use-only purity, why “pharma grade” is often a marketing term on research products, and how to verify what is really in the vial with a per-batch CoA. Research use only.
Ipamorelin is a selective ghrelin-receptor (GHSR) agonist; sermorelin is a GHRH analogue acting upstream on the pituitary. Mechanism, GH-release shape, side-effect comparison, and why the two are co-studied as a complementary pair. Research use only.
Both are ghrelin-receptor (GHSR) agonists, but hexarelin is the more potent GH releaser with CD36 cardiac activity, while ipamorelin is the cleaner, selective option with slower desensitisation. Mechanism, side effects and desensitisation compared. Research use only.
Both prompt the pituitary through the GHRH receptor, but tesamorelin is a stabilised, more potent molecule with dedicated visceral-fat research, while sermorelin is the shorter GHRH 1-29 fragment. Mechanism, potency and half-life compared. Research use only.
A 39-amino-acid dual agonist developed by Eli Lilly, approved as Mounjaro and Zepbound. Mechanism, half-life, the SURPASS and SURMOUNT trial data, the SURMOUNT-5 head-to-head against semaglutide, and the GLP-1 RC-T research-compound posture.
The 31-amino-acid peptide behind Ozempic, Wegovy and Rybelsus. Mechanism, half-life, the STEP / SUSTAIN / SELECT evidence base, oral vs injectable formulation, and the GLP-1 RC-S research-compound posture.
The most-studied GHRH + GHRP research combination. CJC-1295 with DAC vs no-DAC explained, ipamorelin’s selective ghrelin-receptor mechanism, why the pairing has mechanistic logic rather than just marketing logic, and how the pair compares to tesamorelin and sermorelin.
Amino acids are the monomers; peptides are short chains of them joined by peptide bonds. The plain-English hierarchy - amino acid → peptide → protein - and why sequence is a compound’s identity when reading peptide research.
Yes - semaglutide is a 31-amino-acid peptide and a GLP-1 receptor agonist. What GLP-1 actually is, how the class works, and why an approved medicine is a different category from a research reagent.
“What is better, TRT or peptides?” is partly a category error. A neutral explainer on how clinics and the literature frame testosterone replacement, enclomiphene and peptide signalling - mechanisms, not a verdict.
No - amino-acid chains versus a cholesterol-derived ring system, with different receptors and signalling routes. Why the categories get confused, and the one-sentence way to tell them apart.
Two heavily studied metabolic peptides side by side: how they are alike, how they differ, and what papers usually measure - without treating either as a consumer product.
Research use only. These articles summarise public literature and catalogue facts. They do not diagnose, treat, or prevent any disease, and are not medical advice.